lenalidomide has been researched along with Head and Neck Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, EE; de Souza, J; Goloubeva, O; Jain, A; Kronsberg, S; Nagilla, M; Saloura, V; Seiwert, T; Silpino, L; Taylor, RJ; Villaflor, V; Vokes, E; Wong, S | 1 |
| Bertino, EM; Carson, WE; Davis, M; Grever, M; McMichael, EL; Mo, X; Otterson, GA; Paul, B; Trikha, P | 1 |
2 trial(s) available for lenalidomide and Head and Neck Neoplasms
| Article | Year |
|---|---|
Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Female; Genotype; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Killer Cells, Natural; Lenalidomide; Male; Middle Aged; Receptors, IgG; Squamous Cell Carcinoma of Head and Neck; Thalidomide; Treatment Outcome | 2015 |
A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.
Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Cytokines; Female; Head and Neck Neoplasms; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Staging; Retreatment; T-Lymphocyte Subsets; Thalidomide; Treatment Outcome | 2016 |